검색어: fondaparinuksa (슬로베니아어 - 영어)

korist fondaparinuksa pri av
the mortality benefit shown in the fondaparinux group was maintained until the end of follow-up at day 180. lo in patients who were revascularised with a thrombolytic, fondaparinux significantly reduced the incidence of death/ re-mi at day 30 from 13.6% for the control group to 10.9% (hazard ratio 0.79, no

učinkovitosti in varnosti fondaparinuksa.
4.5 interaction with other medicinal products and other forms of interaction

fondaparinuksa enkrat na dan, so:
pharmacokinetic parameters estimates of fondaparinux in patients with vte receiving the fondaparinux proposed dose regimen once daily are:

fondaparinuksa se ne sme injicirati intramuskularno.
fondaparinux must not be administered intramuscularly.

fondaparinuksa se ne sme injicirati intramuskularno. av
fondaparinux must not be administered intramuscularly. du

izločanje fondaparinuksa se zmanjšuje s telesno maso.
elimination of fondaparinux decreases with weight.

varnost fondaparinuksa 2,5 mg so ocenjevali pri:
the safety of fondaparinux 2.5 mg has been evaluated in:

otroci - uporabe fondaparinuksa pri otrocih niso proučevali.
paediatric patients - fondaparinux has not been investigated in this population.

otroci - uporabe fondaparinuksa pri otrocih niso proučevali. ilo
elderly patients - renal function may decrease with age and thus, the elimination capacity for ct

10 mg natrijevega fondaparinuksa v 0,8 ml raztopine za injiciranje.
10 mg fondaparinux sodium in 0.8 ml solution for injection

ustrezni podatki o uporabi fondaparinuksa pri nosečnicah niso na voljo.
there are no adequate data from the use of fondaparinux in pregnant women.

na voljo ni podatkov o vplivu fondaparinuksa na plodnost pri človeku.
there are no data available on the effect of fondaparinux on human fertility.

fondaparinuksa nosečnicam ne smemo predpisovati, razen kadar je nedvoumno potrebno.
fondaparinux should not be prescribed to pregnant women unless clearly necessary.

prvi odmerek fondaparinuksa mora bolnik prejeti intravensko, nadaljnje odmerke pa subkutano.
the first dose of fondaparinux is administered intravenously and subsequent doses are administered by subcutaneous injection.

pilotska študija določitve odmerka in farmakokinetike fondaparinuksa pri otrocih z globoko vensko trombozo
a pilot dose-finding and pharmacokinetic study of fondaparinux in children with deep vein thrombosis

ena napolnjena injekcijska brizga (0,4 ml) vsebuje 5 mg natrijevega fondaparinuksa.
one pre-filled syringe (0.4 ml) contains 5 mg fondaparinux sodium.

ena napolnjena injekcijska brizga (0,3 ml) vsebuje 1,5 mg natrijevega fondaparinuksa.
each pre-filled syringe (0.3 ml) contains 1.5 mg of fondaparinux sodium.

učinek fondaparinuksa je rezultat selektivne inhibicije faktorja xa preko antitrombina iii (atiii).
the antithrombotic activity of fondaparinux is the result of antithrombin iii (atiii) mediated selective inhibition of factor xa.

antitrombotični učinek fondaparinuksa je rezultat selektivne inhibicije faktorja xa preko antitrombina iii (antitrombin).
the antithrombotic activity of fondaparinux is the result of antithrombin iii (antithrombin) mediated selective inhibition of factor xa.

za časom, ko je bolnik prejel zadnji odmerek fondaparinuksa (glejte poglavje 4. 4).
the timing of